The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
- 1 April 1994
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 4 (3) , 194-199
- https://doi.org/10.1046/j.1525-1438.1994.04030194.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Serum CA 125 Level Allows Early Identification of Nonresponders during Induction ChemotherapyGynecologic Oncology, 1993
- Is Serum CA 125 at the Time of Relapse a Prognostic Indicator for Further Survival Prognosis in Patients with Ovarian Cancer?Gynecologic Oncology, 1993
- CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancerGynecologic Oncology, 1992
- NEU protein overexpression in benign, borderline, and malignant ovarian neoplasmsGynecologic Oncology, 1992
- Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tractGynecologic Oncology, 1991
- c‐erbB‐2 oncogene expression in ovarian cancerThe Journal of Pathology, 1990
- Protooncogene amplification and tumor ploidy in human ovarian neoplasmsHuman Pathology, 1990
- Theneu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patientsInternational Journal of Cancer, 1990
- The subcellular localization of the neu protein in human normal and neoplastic cellsInternational Journal of Cancer, 1989
- A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomasCancer, 1988